Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer

[1]  J. Gerdes,et al.  The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins , 1993, The Journal of cell biology.

[2]  S. Nordling,et al.  Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. , 1993, British Journal of Cancer.

[3]  Y. Remvikos.  Prognostic value of the S-phase fraction of breast cancer. , 1993, British Journal of Cancer.

[4]  P. Lampertico,et al.  Proliferation index as a prognostic marker in breast cancer , 1993, Cancer.

[5]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[6]  P. Boracchi,et al.  Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: histologic, clinical and prognostic correlations , 1992 .

[7]  C. Osborne,et al.  Prognostic factors for breast cancer: have they met their promise? , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F Pozza,et al.  Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. , 1991, Anticancer research.

[9]  M. Mitze,et al.  Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67 , 1991, Breast Cancer Research and Treatment.

[10]  G. Hortobagyi,et al.  Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis , 1991, Cancer.

[11]  J. Gerdes,et al.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. , 1991, The American journal of pathology.

[12]  J. Schulte‐Mönting,et al.  Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.

[13]  S. Chevillard,et al.  Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. , 1990, American journal of clinical pathology.

[14]  M. Fernö,et al.  Indicators of prognosis in node-negative breast cancer. , 1990, The New England journal of medicine.

[15]  I. Ellis,et al.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations. , 1989, British Journal of Cancer.

[16]  G M Clark,et al.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.

[17]  J. Meyer,et al.  Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Comparisons and correlations. , 1988, American journal of clinical pathology.

[18]  H. Magdelenat,et al.  Estrogen and progestin receptor assay in fine needle aspirates of breast cancer: methodological aspects. , 1987, European journal of cancer & clinical oncology.

[19]  M. Tubiana,et al.  The long‐term prognostic significance of the thymidine labelling index in breast cancer , 1984, International journal of cancer.

[20]  M. M. McCrate,et al.  Prediction of early course of breast carcinoma by thymidine labeling , 1983, Cancer.

[21]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[22]  W. Göhde,et al.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle , 1975, Radiation and environmental biophysics.

[23]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[26]  M. Gnant,et al.  Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis , 2004, Breast Cancer Research and Treatment.

[27]  T. Venesio,et al.  Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. , 1993, European journal of cancer.

[28]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .